Targeting Intracellular Signaling Molecules in the Pursuit of Disease Remission and Comorbid Management of Patients with Rheumatoid Arthritis
Wednesday, March 27
5:30 pm – 6:00 pm Registration/Dinner
6:00 pm – 7:30 pm Meeting
255 Biscayne Blvd Way
Miami, FL 33131
Meeting Room: Jnr Ballroom A, B, & C
VIRTUAL REALITY SETS provided to all attendees for viewing this presentation only
- Interactive, case-based learning environment
- Create your own Personalized Poster
- iPads provided to enhance learning experience and enable real-time Q&A
LIVE EVENT REGISTRATION
To preregister for the live event, please visit www.MLG-RA.com or call 207-406-4248
PROGRAM CHAIR
Maria Greenwald, MD, FACR
MAVEN Rheumatology Consultant
Medical Director, Desert Medical Advances
Palm Desert, CA
FACULTY
Andreas Reimold, MD
Professor
Rheumatic Diseases Division
Department of Internal Medicine
University of Texas Southwestern
Medical Center
Dallas, Texas
AGENDA
- A chronic inflammatory Disease-Rheumatoid arthritis
- Biological pathways that result in pathology
- JAK/STAT pathway inhibition—molecular and pharmacodynamics effects
- Blockade of the JAK/STAT pathway
- JAK inhibitors—profiling their specificity
- Clinical trials review of approved JAK inhibitors—application in the patient care setting
- Tofacitinib data review in moderate-to-severe RA
- Baricitinib data review in moderate-to-severe RA
- Up and coming agents
- Comorbid considerations and selective JAK inhibition in RA
- Monitoring for achievement of treatment agents
- Conclusion and Q&A
TARGET AUDIENCE
This activity is designed to meet the educational needs of rheumatologists, internists, and allied healthcare professionals involved in the care of patients with rheumatoid arthritis.
LEARNING OBJECTIVES
Upon completion of the program, attendees should be able to:
- Review the systemic pathogenesis of rheumatoid arthritis as driven by inflammatory effector pathways
- Discuss the clinical trials data for the efficacy and safety of JAK pathway inhibition in the treatment of moderate-to-severe rheumatoid arthritis
- Describe the disease-related comorbid changes, their associated risks and management in patients with rheumatoid arthritis
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.5 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the long-term treatment and management of patients with rheumatoid arthritis. CNE Credits: 1.5 ANCC Contact Hours.
CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (i.e. physical, dietary, etc.) Please contact Med Learning Group prior to the live event at info@medlearninggroup.com
Targeting Intracellular Signaling Molecules in the Pursuit of Disease Remission and Comorbid Management of Patients with Rheumatoid Arthritis
Wednesday, April 24
5:30 pm – 6:00 pm Registration/Dinner
6:00 pm – 7:30 pm Meeting
500 Canal Street
New Orleans, LA, 70130
Meeting Room: Rhythms 2 & 3
VIRTUAL REALITY SETS provided to all attendees for viewing this presentation only
- Interactive, case-based learning environment
- Create your own Personalized Poster
- iPads provided to enhance learning experience and enable real-time Q&A
LIVE EVENT REGISTRATION
To preregister for the live event, please visit www.MLG-RA.com or call 207-406-4248
Faculty
Myriam E. Guevara, MD
Assistant Professor of Clinical Medicine
LSU Health Network Clinic
Program Director, Rheumatology LSU
New Orleans, LA
Maria Greenwald, MD, FACR
MAVEN Rheumatology Consultant
Medical Director, Desert Medical Advances
Palm Desert, CA
AGENDA
- A chronic inflammatory Disease-Rheumatoid arthritis
- Biological pathways that result in pathology
- JAK/STAT pathway inhibition—molecular and pharmacodynamics effects
- Blockade of the JAK/STAT pathway
- JAK inhibitors—profiling their specificity
- Clinical trials review of approved JAK inhibitors—application in the patient care setting
- Tofacitinib data review in moderate-to-severe RA
- Baricitinib data review in moderate-to-severe RA
- Up and coming agents
- Comorbid considerations and selective JAK inhibition in RA
- Monitoring for achievement of treatment agents
- Conclusion and Q&A
TARGET AUDIENCE
This activity is designed to meet the educational needs of rheumatologists, internists, and allied healthcare professionals involved in the care of patients with rheumatoid arthritis.
LEARNING OBJECTIVES
Upon completion of the program, attendees should be able to:
- Review the systemic pathogenesis of rheumatoid arthritis as driven by inflammatory effector pathways
- Discuss the clinical trials data for the efficacy and safety of JAK pathway inhibition in the treatment of moderate-to-severe rheumatoid arthritis
- Describe the disease-related comorbid changes, their associated risks and management in patients with rheumatoid arthritis
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.5 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the long-term treatment and management of patients with rheumatoid arthritis. CNE Credits: 1.5 ANCC Contact Hours.
CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (i.e. physical, dietary, etc.) Please contact Med Learning Group prior to the live event at info@medlearninggroup.com
Targeting Intracellular Signaling Molecules in the Pursuit of Disease Remission and Comorbid Management of Patients with Rheumatoid Arthritis
Wednesday, May 8
5:30 PM – 6:00 PM Registration/Dinner
6:00 PM – 7:30 PM Meeting
Houston Marriott Medical Center/Museum District
6580 Fannin Street, (Driveway Entrance on 1730 Dryden Road)
Houston, TX 77030
Meeting Room: Salons E-G
1.50 CME Credits features:
VIRTUAL REALITY SETS provided to all attendees for viewing this presentation only
- Interactive, case-based learning environment
- Create your own Personalized Poster
- iPads provided to enhance learning experience and enable real-time Q&A
LIVE EVENT REGISTRATION
To preregister for the live event, please visit www.MLG-RA.com or call 207-406-4248
CO-CHAIRS
Daniel E. Furst, MD
Professor of Rheumatology and Medicine
University of California, Los Angeles
University of Washington, Seattle WA
University of Florence, Florence, Italy
Maria Greenwald, MD, FACR
MAVEN Rheumatology Consultant
Medical Director, Desert Medical Advances
Palm Desert, CA
AGENDA
- A chronic inflammatory Disease-Rheumatoid arthritis
- Biological pathways that result in pathology
- JAK/STAT pathway inhibition—molecular and pharmacodynamics effects
- Blockade of the JAK/STAT pathway
- JAK inhibitors—profiling their specificity
- Clinical trials review of approved JAK inhibitors—application in the patient care setting
- Tofacitinib data review in moderate-to-severe RA
- Baricitinib data review in moderate-to-severe RA
- Up and coming agents
- Comorbid considerations and selective JAK inhibition in RA
- Monitoring for achievement of treatment agents
- Conclusion and Q&A
TARGET AUDIENCE
This activity is designed to meet the educational needs of rheumatologists, internists, and allied healthcare professionals involved in the care of patients with rheumatoid arthritis.
LEARNING OBJECTIVES
Upon completion of the program, attendees should be able to:
- Review the systemic pathogenesis of rheumatoid arthritis as driven by inflammatory effector pathways
- Discuss the clinical trials data for the efficacy and safety of JAK pathway inhibition in the treatment of moderate-to-severe rheumatoid arthritis
- Describe the disease-related comorbid changes, their associated risks and management in patients with rheumatoid arthritis
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.5 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the long-term treatment and management of patients with rheumatoid arthritis. CNE Credits: 1.5 ANCC Contact Hours.
CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (i.e. physical, dietary, etc.) Please contact Med Learning Group prior to the live event at info@medlearninggroup.com
Targeting Intracellular Signaling Molecules in the Pursuit of Disease Remission and Comorbid Management of Patients with Rheumatoid Arthritis
Wednesday, June 26
5:30 pm – 6:00 pm Registration/Dinner
6:00 pm – 7:30 pm Meeting
SLS Hotel Beverly Hills
465 S. La Cienega Boulevard
Los Angeles, CA, 90048
Meeting Room: Albert Ballroom
1.50 CME Credits features:
VIRTUAL REALITY SETS provided to all attendees for viewing this presentation only
- Interactive, case-based learning environment
- Create your own Personalized Poster
- iPads provided to enhance learning experience and enable real-time Q&A
LIVE EVENT REGISTRATION
To preregister for the live event, please visit www.MLG-RA.com or call 207-406-4248
CO-CHAIRS
Daniel E. Furst, MD
Professor of Rheumatology and Medicine
University of California, Los Angeles
University of Washington, Seattle WA
University of Florence, Florence, Italy
Maria Greenwald, MD, FACR
MAVEN Rheumatology Consultant
Medical Director, Desert Medical Advances
Palm Desert, CA
AGENDA
- A chronic inflammatory Disease-Rheumatoid arthritis
- Biological pathways that result in pathology
- JAK/STAT pathway inhibition—molecular and pharmacodynamics effects
- Blockade of the JAK/STAT pathway
- JAK inhibitors—profiling their specificity
- Clinical trials review of approved JAK inhibitors—application in the patient care setting
- Tofacitinib data review in moderate-to-severe RA
- Baricitinib data review in moderate-to-severe RA
- Up and coming agents
- Comorbid considerations and selective JAK inhibition in RA
- Monitoring for achievement of treatment agents
- Conclusion and Q&A
TARGET AUDIENCE
This activity is designed to meet the educational needs of rheumatologists, internists, and allied healthcare professionals involved in the care of patients with rheumatoid arthritis.
LEARNING OBJECTIVES
Upon completion of the program, attendees should be able to:
- Review the systemic pathogenesis of rheumatoid arthritis as driven by inflammatory effector pathways
- Discuss the clinical trials data for the efficacy and safety of JAK pathway inhibition in the treatment of moderate-to-severe rheumatoid arthritis
- Describe the disease-related comorbid changes, their associated risks and management in patients with rheumatoid arthritis
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.5 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the long-term treatment and management of patients with rheumatoid arthritis. CNE Credits: 1.5 ANCC Contact Hours.
CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (i.e. physical, dietary, etc.) Please contact Med Learning Group prior to the live event at info@medlearninggroup.com
Targeting Intracellular Signaling Molecules in the Pursuit of Disease Remission and Comorbid Management of Patients with Rheumatoid Arthritis
Wednesday, July 31
5:30 pm – 6:00 pm Registration/Dinner
6:00 pm – 7:30 pm Meeting
11 South LaSalle Street
Chicago, IL 60603
Meeting Room: LaSalle I & II
1.50 CME Credits features:
VIRTUAL REALITY SETS provided to all attendees for viewing this presentation only
- Interactive, case-based learning environment
- Create your own Personalized Poster
- iPads provided to enhance learning experience and enable real-time Q&A
LIVE EVENT REGISTRATION
To preregister for the live event, please visit www.MLG-RA.com or call 207-406-4248
PROGRAM CHAIR
Maria Greenwald, MD, FACR
MAVEN Rheumatology Consultant
Medical Director, Desert Medical Advances
Palm Desert, CA
FACULTY
Andreas Reimold, MD
Professor
Rheumatic Diseases Division
Department of Internal Medicine
University of Texas Southwestern
Medical Center
Dallas, Texas
AGENDA
- A chronic inflammatory Disease-Rheumatoid arthritis
- Biological pathways that result in pathology
- JAK/STAT pathway inhibition—molecular and pharmacodynamics effects
- Blockade of the JAK/STAT pathway
- JAK inhibitors—profiling their specificity
- Clinical trials review of approved JAK inhibitors—application in the patient care setting
- Tofacitinib data review in moderate-to-severe RA
- Baricitinib data review in moderate-to-severe RA
- Up and coming agents
- Comorbid considerations and selective JAK inhibition in RA
- Monitoring for achievement of treatment agents
- Conclusion and Q&A
TARGET AUDIENCE
This activity is designed to meet the educational needs of rheumatologists, internists, and allied healthcare professionals involved in the care of patients with rheumatoid arthritis.
LEARNING OBJECTIVES
Upon completion of the program, attendees should be able to:
- Review the systemic pathogenesis of rheumatoid arthritis as driven by inflammatory effector pathways
- Discuss the clinical trials data for the efficacy and safety of JAK pathway inhibition in the treatment of moderate-to-severe rheumatoid arthritis
- Describe the disease-related comorbid changes, their associated risks and management in patients with rheumatoid arthritis
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.5 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the long-term treatment and management of patients with rheumatoid arthritis. CNE Credits: 1.5 ANCC Contact Hours.
CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (i.e. physical, dietary, etc.) Please contact Med Learning Group prior to the live event at info@medlearninggroup.com
Targeting Intracellular Signaling Molecules in the Pursuit of Disease Remission and Comorbid Management of Patients with Rheumatoid Arthritis
Wednesday, August 7, 2019
5:30 PM – 6:00 PM Registration/Dinner
6:00 PM – 7:30 PM Meeting
THE WESTIN BUCKHEAD ATLANTA
3391 Peachtree Road, NE
Atlanta, GA 30326
Meeting Room: Ballroom C & D
1.50 CME Credits features:
VIRTUAL REALITY SETS provided to all attendees for viewing this presentation only
- Interactive, case-based learning environment
- Create your own Personalized Poster
- iPads provided to enhance learning experience and enable real-time Q&A
LIVE EVENT REGISTRATION
To preregister for the live event, please visit www.MLG-RA.com or call 207-406-4248
PROGRAM CHAIR
Daniel E. Furst, MD
Professor of Rheumatology and Medicine
University of California, Los Angeles
University of Washington, Seattle WA
University of Florence, Florence, Italy
FACULTY
Vivian Bykerk, BSc, MD, FRCPC
Rheumatologist
Hospital for Special Surgery
Associate Professor of Medicine
Director, Inflammatory Arthritis Center of Excellence
Weill Cornell Medical College
New York, NY
Andreas Reimold, MD
Professor
Rheumatic Diseases Division
Department of Internal Medicine
University of Texas Southwestern Medical Center
Dallas, TX
AGENDA
- A chronic inflammatory Disease-Rheumatoid arthritis
- Biological pathways that result in pathology
- JAK/STAT pathway inhibition—molecular and pharmacodynamics effects
- Blockade of the JAK/STAT pathway
- JAK inhibitors—profiling their specificity
- Clinical trials review of approved JAK inhibitors—application in the patient care setting
- Tofacitinib data review in moderate-to-severe RA
- Baricitinib data review in moderate-to-severe RA
- Up and coming agents
- Comorbid considerations and selective JAK inhibition in RA
- Monitoring for achievement of treatment agents
- Conclusion and Q&A
TARGET AUDIENCE
This activity is designed to meet the educational needs of rheumatologists, internists, and allied healthcare professionals involved in the care of patients with rheumatoid arthritis.
LEARNING OBJECTIVES
Upon completion of the program, attendees should be able to:
- Review the systemic pathogenesis of rheumatoid arthritis as driven by inflammatory effector pathways
- Discuss the clinical trials data for the efficacy and safety of JAK pathway inhibition in the treatment of moderate-to-severe rheumatoid arthritis
- Describe the disease-related comorbid changes, their associated risks and management in patients with rheumatoid arthritis
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.5 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the long-term treatment and management of patients with rheumatoid arthritis. CNE Credits: 1.5 ANCC Contact Hours.
CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (i.e. physical, dietary, etc.) Please contact Med Learning Group prior to the live event at info@medlearninggroup.com
Targeting Intracellular Signaling Molecules in the Pursuit of Disease Remission and Comorbid Management of Patients with Rheumatoid Arthritis
Wednesday, September 11, 2019
5:30 pm – 6:00 pm Registration/Dinner
6:00 pm – 7:30 pm Meeting
Venue: TBD
Nashville, TN
MEETING ROOM: TBD
1.50 CME Credits features:
VIRTUAL REALITY SETS provided to all attendees for viewing this presentation only
- Interactive, case-based learning environment
- Create your own Personalized Poster
- iPads provided to enhance learning experience and enable real-time Q&A
LIVE EVENT REGISTRATION
To preregister for the live event, please visit www.MLG-RA-EASE.com or call 207-406-4248
CO-CHAIRS
Daniel E. Furst, MD
Professor of Rheumatology and Medicine
University of California, Los Angeles
University of Washington, Seattle WA
University of Florence, Florence, Italy
Maria Greenwald, MD, FACR
MAVEN Rheumatology Consultant
Medical Director, Desert Medical Advances
Palm Desert, CA
AGENDA
- A chronic inflammatory Disease-Rheumatoid arthritis
- Biological pathways that result in pathology
- JAK/STAT pathway inhibition—molecular and pharmacodynamics effects
- Blockade of the JAK/STAT pathway
- JAK inhibitors—profiling their specificity
- Clinical trials review of approved JAK inhibitors—application in the patient care setting
- Tofacitinib data review in moderate-to-severe RA
- Baricitinib data review in moderate-to-severe RA
- Up and coming agents
- Comorbid considerations and selective JAK inhibition in RA
- Monitoring for achievement of treatment agents
- Conclusion and Q&A
TARGET AUDIENCE
This activity is designed to meet the educational needs of rheumatologists, internists, and allied healthcare professionals involved in the care of patients with rheumatoid arthritis.
LEARNING OBJECTIVES
Upon completion of the program, attendees should be able to:
- Review the systemic pathogenesis of rheumatoid arthritis as driven by inflammatory effector pathways
- Discuss the clinical trials data for the efficacy and safety of JAK pathway inhibition in the treatment of moderate-to-severe rheumatoid arthritis
- Describe the disease-related comorbid changes, their associated risks and management in patients with rheumatoid arthritis
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.5 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the long-term treatment and management of patients with rheumatoid arthritis. CNE Credits: 1.5 ANCC Contact Hours.
CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (i.e. physical, dietary, etc.) Please contact Med Learning Group prior to the live event at info@medlearninggroup.com
Targeting Intracellular Signaling Molecules in the Pursuit of Disease Remission and Comorbid Management of Patients with Rheumatoid Arthritis
Wednesday, October 9, 2019
5:30 pm – 6:00 pm Registration/Dinner
6:00 pm – 7:30 pm Meeting
Sheraton Grand Phoenix
340 North 3rd Street
Phoenix, AZ 85004
Meeting Room: Paradise Valley
1.50 CME Credits features:
VIRTUAL REALITY SETS provided to all attendees for viewing this presentation only
- Interactive, case-based learning environment
- Create your own Personalized Poster
- iPads provided to enhance learning experience and enable real-time Q&A
LIVE EVENT REGISTRATION
To preregister for the live event, please visit www.MLG-RA-EASE.com or call 207-406-4248
CO-CHAIRS
Daniel E. Furst, MD
Professor of Rheumatology and Medicine
University of California, Los Angeles
University of Washington, Seattle WA
University of Florence, Florence, Italy
Maria Greenwald, MD, FACR
MAVEN Rheumatology Consultant
Medical Director, Desert Medical Advances
Palm Desert, CA
AGENDA
- A chronic inflammatory Disease-Rheumatoid arthritis
- Biological pathways that result in pathology
- JAK/STAT pathway inhibition—molecular and pharmacodynamics effects
- Blockade of the JAK/STAT pathway
- JAK inhibitors—profiling their specificity
- Clinical trials review of approved JAK inhibitors—application in the patient care setting
- Tofacitinib data review in moderate-to-severe RA
- Baricitinib data review in moderate-to-severe RA
- Up and coming agents
- Comorbid considerations and selective JAK inhibition in RA
- Monitoring for achievement of treatment agents
- Conclusion and Q&A
TARGET AUDIENCE
This activity is designed to meet the educational needs of rheumatologists, internists, and allied healthcare professionals involved in the care of patients with rheumatoid arthritis.
LEARNING OBJECTIVES
Upon completion of the program, attendees should be able to:
- Review the systemic pathogenesis of rheumatoid arthritis as driven by inflammatory effector pathways
- Discuss the clinical trials data for the efficacy and safety of JAK pathway inhibition in the treatment of moderate-to-severe rheumatoid arthritis
- Describe the disease-related comorbid changes, their associated risks and management in patients with rheumatoid arthritis
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.5 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the long-term treatment and management of patients with rheumatoid arthritis. CNE Credits: 1.5 ANCC Contact Hours.
CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (i.e. physical, dietary, etc.) Please contact Med Learning Group prior to the live event at info@medlearninggroup.com
